{"title":"基于药物遗传变异的英国生物银行药物使用预测的图表示学习。","authors":"Bill Qi, Yannis J Trakadis","doi":"10.3390/bioengineering12060595","DOIUrl":null,"url":null,"abstract":"<p><p>Ineffective treatment and side effects are associated with high burdens for the patient and society. We investigated the application of graph representation learning (GRL) for predicting medication usage based on individual genetic data in the United Kingdom Biobank (UKBB). A graph convolutional network (GCN) was used to integrate interconnected biomedical entities in the form of a knowledge graph as part of a machine learning (ML) prediction model. Data from The Pharmacogenomics Knowledgebase (PharmGKB) was used to construct a biomedical knowledge graph. Individual genetic data (<i>n</i> = 485,754) from the UKBB was obtained and preprocessed to match with pharmacogenetic variants in the PharmGKB. Self-reported medication usage labels were obtained from UKBB data field 20003. We hypothesize that pharmacogenetic variants can predict the impact of medications on individuals. We assume that an individual using a medication on a regular basis experiences a net benefit (vs. side-effects) from the medication. ML models were trained to predict medication usage for 264 medications. The GCN model significantly outperformed both a baseline logistic regression model (<i>p</i>-value: 1.53 × 10<sup>-9</sup>) and a deep neural network model (<i>p</i>-value: 8.68 × 10<sup>-8</sup>). The GCN model also significantly outperformed a GCN model trained using a random graph (GCN-random) (<i>p</i>-value: 5.44 × 10<sup>-9</sup>). A consistent trend of medications with higher sample sizes having better performance was observed, and for several medications, a high relative rank of the medication (among multiple medications) was associated with greater than 2-fold higher odds of usage of the medication. In conclusion, a graph-based ML approach could be useful in advancing precision medicine by prioritizing medications that a patient may need based on their genetic data. However, further research is needed to improve the quality and quantity of genetic data and to validate our approach using more reliable medication labels.</p>","PeriodicalId":8874,"journal":{"name":"Bioengineering","volume":"12 6","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12189576/pdf/","citationCount":"0","resultStr":"{\"title\":\"Graph Representation Learning for the Prediction of Medication Usage in the UK Biobank Based on Pharmacogenetic Variants.\",\"authors\":\"Bill Qi, Yannis J Trakadis\",\"doi\":\"10.3390/bioengineering12060595\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ineffective treatment and side effects are associated with high burdens for the patient and society. We investigated the application of graph representation learning (GRL) for predicting medication usage based on individual genetic data in the United Kingdom Biobank (UKBB). A graph convolutional network (GCN) was used to integrate interconnected biomedical entities in the form of a knowledge graph as part of a machine learning (ML) prediction model. Data from The Pharmacogenomics Knowledgebase (PharmGKB) was used to construct a biomedical knowledge graph. Individual genetic data (<i>n</i> = 485,754) from the UKBB was obtained and preprocessed to match with pharmacogenetic variants in the PharmGKB. Self-reported medication usage labels were obtained from UKBB data field 20003. We hypothesize that pharmacogenetic variants can predict the impact of medications on individuals. We assume that an individual using a medication on a regular basis experiences a net benefit (vs. side-effects) from the medication. ML models were trained to predict medication usage for 264 medications. The GCN model significantly outperformed both a baseline logistic regression model (<i>p</i>-value: 1.53 × 10<sup>-9</sup>) and a deep neural network model (<i>p</i>-value: 8.68 × 10<sup>-8</sup>). The GCN model also significantly outperformed a GCN model trained using a random graph (GCN-random) (<i>p</i>-value: 5.44 × 10<sup>-9</sup>). A consistent trend of medications with higher sample sizes having better performance was observed, and for several medications, a high relative rank of the medication (among multiple medications) was associated with greater than 2-fold higher odds of usage of the medication. In conclusion, a graph-based ML approach could be useful in advancing precision medicine by prioritizing medications that a patient may need based on their genetic data. However, further research is needed to improve the quality and quantity of genetic data and to validate our approach using more reliable medication labels.</p>\",\"PeriodicalId\":8874,\"journal\":{\"name\":\"Bioengineering\",\"volume\":\"12 6\",\"pages\":\"\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12189576/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioengineering\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.3390/bioengineering12060595\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/bioengineering12060595","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
Graph Representation Learning for the Prediction of Medication Usage in the UK Biobank Based on Pharmacogenetic Variants.
Ineffective treatment and side effects are associated with high burdens for the patient and society. We investigated the application of graph representation learning (GRL) for predicting medication usage based on individual genetic data in the United Kingdom Biobank (UKBB). A graph convolutional network (GCN) was used to integrate interconnected biomedical entities in the form of a knowledge graph as part of a machine learning (ML) prediction model. Data from The Pharmacogenomics Knowledgebase (PharmGKB) was used to construct a biomedical knowledge graph. Individual genetic data (n = 485,754) from the UKBB was obtained and preprocessed to match with pharmacogenetic variants in the PharmGKB. Self-reported medication usage labels were obtained from UKBB data field 20003. We hypothesize that pharmacogenetic variants can predict the impact of medications on individuals. We assume that an individual using a medication on a regular basis experiences a net benefit (vs. side-effects) from the medication. ML models were trained to predict medication usage for 264 medications. The GCN model significantly outperformed both a baseline logistic regression model (p-value: 1.53 × 10-9) and a deep neural network model (p-value: 8.68 × 10-8). The GCN model also significantly outperformed a GCN model trained using a random graph (GCN-random) (p-value: 5.44 × 10-9). A consistent trend of medications with higher sample sizes having better performance was observed, and for several medications, a high relative rank of the medication (among multiple medications) was associated with greater than 2-fold higher odds of usage of the medication. In conclusion, a graph-based ML approach could be useful in advancing precision medicine by prioritizing medications that a patient may need based on their genetic data. However, further research is needed to improve the quality and quantity of genetic data and to validate our approach using more reliable medication labels.
期刊介绍:
Aims
Bioengineering (ISSN 2306-5354) provides an advanced forum for the science and technology of bioengineering. It publishes original research papers, comprehensive reviews, communications and case reports. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. All aspects of bioengineering are welcomed from theoretical concepts to education and applications. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. There are, in addition, four key features of this Journal:
● We are introducing a new concept in scientific and technical publications “The Translational Case Report in Bioengineering”. It is a descriptive explanatory analysis of a transformative or translational event. Understanding that the goal of bioengineering scholarship is to advance towards a transformative or clinical solution to an identified transformative/clinical need, the translational case report is used to explore causation in order to find underlying principles that may guide other similar transformative/translational undertakings.
● Manuscripts regarding research proposals and research ideas will be particularly welcomed.
● Electronic files and software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.
● We also accept manuscripts communicating to a broader audience with regard to research projects financed with public funds.
Scope
● Bionics and biological cybernetics: implantology; bio–abio interfaces
● Bioelectronics: wearable electronics; implantable electronics; “more than Moore” electronics; bioelectronics devices
● Bioprocess and biosystems engineering and applications: bioprocess design; biocatalysis; bioseparation and bioreactors; bioinformatics; bioenergy; etc.
● Biomolecular, cellular and tissue engineering and applications: tissue engineering; chromosome engineering; embryo engineering; cellular, molecular and synthetic biology; metabolic engineering; bio-nanotechnology; micro/nano technologies; genetic engineering; transgenic technology
● Biomedical engineering and applications: biomechatronics; biomedical electronics; biomechanics; biomaterials; biomimetics; biomedical diagnostics; biomedical therapy; biomedical devices; sensors and circuits; biomedical imaging and medical information systems; implants and regenerative medicine; neurotechnology; clinical engineering; rehabilitation engineering
● Biochemical engineering and applications: metabolic pathway engineering; modeling and simulation
● Translational bioengineering